Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome

Kexin Ma,1 Weifang Gao,2 Huazhou Xu,2 Wenjie Liang,2, and Guoping Ma1

1The First Hospital of Hebei Medical University, Shijiazhuang 050000, China
2Hebei Key Laboratory of Integrative Medicine of Liver-Kidney Patterns, Institute of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei, China

Correspondence should be addressed to Wenjie Liang; lwj712004@126.com and Guoping Ma; mgp2006@163.com

Received 18 October 2021; Revised 3 December 2021; Accepted 4 January 2022; Published 24 January 2022

Copyright © 2022 Kexin Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiorenal syndrome (CRS), a clinical syndrome involving multiple pathological mechanisms, exhibits high morbidity and mortality. According to the primary activity of the disease, CRS can be divided into cardiorenal syndrome (type I and type II), renal heart syndrome (type III and type IV), and secondary heart and kidney disease (type V). The renin-angiotensin-aldosterone system (RAAS) is an important humoral regulatory system of the body that exists widely in various tissues and organs. As a compensatory mechanism, the RAAS is typically activated to participate in the regulation of target organ function. RAAS activation plays a key role in the pathogenesis of CRS. The RAAS induces the onset and development of CRS by mediating oxidative stress, uremic toxin overload, and asymmetric dimethylarginine production. Research on the mechanism of RAAS-induced CRS can provide multiple intervention methods that are of great significance for reducing end-stage organ damage and further improving the quality of life of patients with CRS.

1. Introduction

The incidence of heart and kidney disease, especially chronic heart failure (CHF) and chronic kidney disease (CKD), is increasing yearly with changes in lifestyle and increases in pressure. CHF is a health problem worldwide, affecting 2% to 3% of adults [1]. CKD is also a global public health problem, and the prevalence of CKD has increased to 8–16% in adults worldwide over the past 2 decades [2]. CHF and chronic renal failure often occur simultaneously or successively. According to statistics, approximately 20% of heart failure (HF) patients have moderate to severe renal dysfunction, and greater than 60% exhibit at least mild renal dysfunction. The incidence of CHF is also 15-fold higher in CKD patients compared with healthy individuals. In addition, the increase in annual mortality related to dialysis is greater than 20%, and half of these deaths are cardiovascular related [3]. Comorbidities of these conditions are an indicator of poor prognosis, prolonged length of stay, and increased morbidity and mortality [4].

Cardiorenal syndrome (CRS) refers to a complex pathophysiological disorder caused by cardiac and renal insufficiency, and these processes interact with each other [5, 6]. CRS is divided into 5 types based on primary disease activity. Type I and type II are referred to as cardiorenal syndrome, type III and type IV are called renal heart syndrome, and type V refers to heart and kidney involvement caused by simultaneous systemic diseases [7]. Homeostasis and hemodynamics in the body are jointly regulated by the interdependence of the heart and kidneys. The heart depends on the kidneys, which generate blood flow and pressure [8]. Primary dysfunction of one organ often leads to secondary dysfunction in another organ, resulting in a vicious cycle and eventually leading to cardiorenal syndrome [4]. Excessive activation of the renin-angiotensin-aldosterone system (RAAS) plays a key role in this process [9].
2. Brief Introduction of the RAAS

The RAAS is an important humoral regulatory system of the body, comprising enzymes and peptides. The system widely exists in various tissues and organs, such as the myocardium, vascular smooth muscle, and kidney, and participates in the regulation of target organ function [10]. When the renin content in the blood increases, angiotensinogen (Ang) produced by the liver is hydrolyzed into angiotensin I (Ang I), which promotes the secretion of epinephrine and norepinephrine. Under the action of angiotensin-converting enzymes (ACEs) produced by the lungs, Ang I is converted into angiotensin II (Ang II) [11]. Ang II is converted into angiotensin III (Ang III) under the action of aminopeptidase.

Ang II is considered to be the most important effector of the RAAS [12]. Ang II-stimulated AT₂R regulates several physiological processes, including vasoconstrictive effect, ventricular hypertrophy, myocardial infarction, atherosclerosis, reactive oxygen species (ROS) generation, tissue inflammation, and aldosterone synthesis [10, 12–14]. Ang II-regulated AT₁R promotes nitric oxide production and counteracts inflammation [15]. It is worth mentioning that activated AT₁R may facilitate the internalization of ACE₂ that is a cellular entry receptor for SARS-CoV-2, further stimulating ACE₂-related internalization of SARS-CoV-2 into affected cells [16, 17]. The adrenal AT₂R is regulated to promote aldosterone synthesis and secretion through Gq/11 protein and β-arrestin signaling [18].

Aldosterone exerts physiological and pathological effects by activating the mineralocorticoid receptor (MR). The activation of MR can induce cardiac, vasculature, and kidney inflammation and fibrosis and increase the susceptibility to atrial and ventricular arrhythmias through sympathoexcitation [12, 19–22]. Aldosterone can increase the production of ROS which induces a loss of dysregulated dynamics and bioenergetics in the organelle and promotes in mitochondrial the production of high energy phosphates [19, 23, 24]. These effects can lead to mitochondrial and adrenergic receptor dysfunction and coronary vasoconstriction which can lead to HF. Moreover, aldosterone stimulates epidermal growth factor receptor activation through activating MR, which regulates the RAAS and ultimately modulates cardiac physiology [24].

Therefore, the RAAS plays a significant role in maintaining homeostasis of cardiovascular function and the balance of electrolytes and bodily fluids and regulating blood pressure, renal blood flow, and urine production [9, 11, 19, 25, 26].

3. Regulation of Renin Secretion

The process of renin secretion is regulated by the stretch receptors of the vascular wall, dense plaque receptors, and sympathetic nerves [27, 28]. The stretch sensor can sense changes in renal blood flow. When the renal blood flow is decreased, stimulation of the stretch sensor on the wall of the arteriolar arteries is weakened. This information is transmitted to juxtaglomerular cells, which increases the amount of renin excreted in their secreted particles. Dense plaques sense changes in NaCl content in tubule fluid. When renal blood flow is reduced, the Na⁺ content in the tubule fluid is decreased, and the dense spot receptor is further activated. This information is transmitted to periglomerular cells, leading to an increase in renin secretion. When the circulating blood volume is decreased, the sympathetic nervous system (SNS) is activated in a compensatory manner and also promotes renin secretion (Figure 1) [29].

3.1. RAAS Activation in CHF. The increases in renal sympathetic nerve activity responsiveness to CHF, which contributes to renin release, further activating RAAS [30, 31]. Under the action of norepinephrine and epinephrine released by Ang I and renal vasoconstriction effect of Ang II, myocardial contractility is enhanced, and peripheral blood vessels are constricted to maintain blood pressure [31] (Figure 1). These effects also result in reduced renal perfusion which contribute to the renal failure [31, 32]. Interestingly, studies of HF in sheep indicate that elevated levels of norepinephrine and Ang II can moderate the renal vascular responses by downregulation of AT₁R in the renal medulla and a decrease in renal vascular responsiveness to α1-adrenoceptor stimulation, which act to maintain renal function [31].

3.2. RAAS Activation in CKD. CKD is a pathological condition associated with an unexplained decrease in the glomerular filtration rate (GFR) (<0.06 L/min) for more than three months. Due to reduced renal blood flow and GFR, the stretch receptors of the arteriolar artery and dense plaques are excited, renin secretion increases, and the RAAS is subsequently activated [27, 28]. Under the combined action of Ang II and Ang III, the stability of renal blood flow and the GFR are maintained [31]. As a result, sodium-water retention and toxin accumulation increase the hemodynamic load.

4. The Role of RAAS-Mediated Oxidative Stress in CRS

4.1. RAAS-Mediated Oxidative Stress. Excessive activation of RAAS causes abnormal production of Ang II and aldosterone in the blood circulation, which can activate nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the heart, promoting ROS generation and leading to oxidative stress [11, 24, 33]. Oxidative stress promotes the development of arteriosclerosis and cardiac fibrosis, accelerating the occurrence and development of CRS [34, 35]. The positive feedback mechanism between oxidative stress and RAAS accelerates the process of CRS [36].

4.2. The Functions of Oxidative Stress-Induced Arteriosclerosis in CHF and CKD. The biological characteristics of lipids and lipoproteins in the circulating blood are altered by oxidative stress. In human and in vitro studies, oxidized low-density lipoprotein (OX-LDL) enters the vascular endothelium, and the cholesterol it carries accumulates in the arterial wall [37, 38]. Modified LDL stimulates the production of vascular cell adhesion molecules, such as
VCAM-1 and P- and E-selectins, on endothelial cells, which results in the recruitment of leukocytes into the subendothelial space. Then, inflammatory cells migrate into the intima [39]. This process is mediated by monocyte chemoattractant proteins. After transformation from monocytes, macrophages express SRA, CD36, LOX-1, and other scavenger receptors, which act through modified LDL internalization. Such cells that harbor lipids are called foam cells, which represent an initial stage of atherosclerotic lesion formation through cytological researches [40, 41]. Oxidative stress in atherogenesis stimulates matrix metalloproteinase release, which leads to a sudden expansion of lesions and promotes arterial thrombosis [42]. Arteriosclerosis aggravates the afterload of the heart and induces compensatory hypertrophy of the heart, further promoting CHF (Figure 2). After the onset of CHF, the circulating blood flow is reduced, and the renal blood flow is decreased, promoting the onset of CKD.

4.3. The Effects of Oxidative Stress-Induced Cytokines in CHF and CKD. Oxidative stress causes vascular damage, and the secretion of proinflammatory cytokines, such as interleukin-6 (IL-6) and transforming growth factor-β (TGF-β), activates fibroblasts and muscle fibroblasts, upregulates collagen production and secretion, and promotes fibrosis of the heart and kidney in rat and human cell studies (Figure 2) [11, 43, 44]. Moreover, human and animal studies have shown that these proinflammatory cytokines subsequently contribute to oxidative stress by increasing NADPH oxidase-generated ROS [45, 46]. Myocardial fibrosis restricts ventricular dilatation, reduces cardiac output, decreases renal blood flow, and causes CKD. Glomerular fibrosis and tubulointerstitial fibrosis lead to decreased renal filtration function, increased fluid retention and preload of the heart, and accelerated cardiac function deterioration [47]. In addition, proinflammatory cytokines aggravate oxidative stress and form a positive feedback loop, eventually leading to a vicious cycle in the study of animals [48].

5. The Role of RAAS-Mediated Uremic Toxin Retention in CRS

5.1. RAAS-Mediated Uremic Toxin Retention. Uremic toxin refers to metabolic waste that cannot be fully excreted from the body and thus accumulates, causing various symptoms and signs due to a decrease in the number of functional nephrons. Activation of the RAAS causes contraction of the glomerular afferent arterioles, which aggravates renal ischemia and therefore reduces glomerular filtration function. In addition, the decrease in renal blood flow increases the incidence of tubular injury in human study [49]. Both of these effects synergistically cause uremic toxin retention via factors, such as fibroblast growth factor-23 (FGF-23), indocyanine sulfate (IS), and p-cresol sulfate (P-CS).

5.2. The Relationship between FGF-23 and CRS. FGF-23 is a bone-derived phosphate-regulating hormone that often occurs in bone metabolic disorders caused by CKD in cat study [50]. FGF-23 promotes the formation of new blood vessels, repairs damaged endothelial cells, and promotes cardiac fibrosis [51]. In human and rat studies, elevated FGF-23 is an independent risk factor for atrial fibrillation (AF), as it
5.3. The Relationship between Protein-Bound Uremic Toxin (PBUT) and CRS. IS and P-CS are PBUTs, and their binding affinity for albumin may be greater than 90% in human studies [58]. After binding to albumin, PBUTs are difficult to clear via glomerular filtration and dialysis. PBUT capacity overload has been identified as a risk factor for heart, kidney, and vascular damage. Cell research shows that PBUTs induce ROS and cause oxidative stress, which affects heart and kidney function [59]. IS participates in the development of mouse myocardial fibrosis by activating nuclear factor-κB (NF-κB) and the transforming growth factor-β pathway; P-CS participates in mouse myocardial cell apoptosis [60]. In addition, the physiological functions of endothelial cells and vascular smooth muscle cells are altered by IS and P-CS, affecting their related genes and leading to endothelial dysfunction (Figure 2) [59]. The pathological effects of PBUT reduce the circulating blood volume and further aggravate CRS.

6. The Role of RAAS-Mediated Asymmetric Dimethylarginine (ADMA) in CRS

6.1. RAAS-Mediated ADMA Generation. ADMA is an endogenous nitric oxide (NO) synthase inhibitor. In CRS, excessive activation of RAAS leads to dysregulation of human dimethylarginine dimethylaminohydrolase (DDAH) and arginine methyltransferase (PRMT), which increase the production of ADMA, affecting CRS evolution by reducing NO bioavailability (Figure 2) [61].

6.2. The Effects of ADMA in Endothelial Dysfunction. ADMA inhibits NO production by competing with the substrate L-arginine in human studies [61, 62]. In the human cardiovascular system, NO plays an important role in vascular tone and remodeling and myocardial contractility. NO has several functions, such as regulating hemodynamics, reabsorption of substances, and renin secretion in the kidney [61, 63]. Human myocardial cells isolated from the heart under stress have shown reduced endothelial nitric oxide synthase (eNOS) activity and expression, indicating a decrease in NO. Reduced NO can induce endothelial dysfunction (ED) and oxidative stress [62]. Endothelial injury acts as an initial trigger causing the accumulation and infiltration of multiple-modified low-density lipoprotein particles in the subendothelial space [64]. Oxidative stress aggravates vascular endothelial damage and promotes the onset and development of CHF and CKD, thus promoting CRS development.
ED often leads to lower GFR and diuretic effects, which cause fluid retention and an increased preload [65]. Human and rat studies show that ED can also lead to decreased eNOS expression and thus induce reduced expression of vasodilatory factors, such as NO; abnormal endothelium-dependent vasodilation; and the onset of arteriosclerosis and calcification [66, 67]. ED in animal is a key process involved in the development of CRS, and it plays a vital role in the connection between cardiovascular disease and CKD (Figure 2) [68].

7. Conclusion

Research on the mechanism of RAAS-induced CRS can provide multiple intervention methods to clinically reduce end-organ damage, thereby ensuring the quality of life of patients with CRS. At present, RAAS inhibitors include angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and mineralocorticoid receptor antagonists (MRA). A meta-analysis showed that RAAS blockers are beneficial to alleviate renal function in patients with HF, protect the cardiovascular system from aldosterone-induced pathological remodeling, and reduce the incidence of sudden cardiac death, thereby prolonging survival and reducing mortality [12, 47, 69–71]. Although RAAS inhibitors have significant clinical efficacy, their application is limited due to their limitations.

Finerenone is a nonsteroidal, selective MRA that may have lower risk of hyperkalemia, have more efficient hypotensive effectiveness, and be beneficial to reduce progression of CKD [72]. Large analysis of over 300 000 HF patients points out that compared with RAAS inhibitors, ARB valsartan combined with the nepriyisin inhibitor sacubitril is more beneficial to patients with HF and also significantly reduce the rates of GFR decline in CHF, further moderate end-stage kidney disease [13, 72–74]. Also, other therapeutic options include some antidiabetic drugs, for example, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and canagliflozin that have been shown highly effective in CRS [72, 75–78].

In addition to effective drug to inhibit RAAS, early recognition of RAAS activation is also critical through biomarkers. Studies have showed that the renal resistive index (RRI) may accurately evaluate very early renal damage secondary to CRS as elevated RAAS and may be more sensitive than creatinine in dogs [79–82]. ACE-I and MRA (spironolactone) can be administered early to improve renal function and delay the progression of CRS by monitoring RRI indicators [81]. Urinary angiotenisogen (U-AGT) has been considered not only a biomarker of intrarenal RAAS modulation but also an important biomarker for risk stratification in HF [36, 83, 84]. Studies of patients with renal function impairment showed that U-AGT has a significant positive correlation with urinary hydrogen peroxide (UH2O2) that can reflect both systemic and renal oxidative stress [36, 85]. Large body of evidence indicates that the combination of RAAS blockers with vitamin D and/or antioxidants might be useful to reduce RAAS activation and oxidative stress and prevent further cardiac and renal deterioration in CRS through detecting U-AGT and UH2O2 [36, 86, 87].

Conflicts of Interest

There is no conflict of interest in the article.

Authors’ Contributions

Kexin Ma and Weifang Gao contributed equally to this work.

Acknowledgments

This study is supported by the Key R&D Program of Hebei Province-General Projects in the Field of Health (213777550), Key Projects of Science and Technology Research in Colleges and University of Hebei Province (ZD2021330), and Hebei Science and Technology Planning Project (152777208).

References

[1] V. Melanovsky, L. Cervenka, O. Viklicky et al., “Kidney response to heart failure: proteomic analysis of cardiorenal syndrome,” Kidney & Blood Pressure Research, vol. 43, no. 5, pp. 1437–1450, 2018.
[2] K. Taguchi, B. C. Elias, C. R. Brooks, S. Ueda, and K. Fukami, “Uremic toxin-targeting as a therapeutic strategy for preventing cardiorenal syndrome,” Circulation Journal, vol. 84, no. 1, pp. 2–8, 2019.
[3] F. Savira, R. Magaye, D. Liew et al., “Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature,” British Journal of Pharmacology, vol. 177, no. 13, pp. 2906–2922, 2020.
[4] J. C. Harrison, S. D. G. Smart, E. M. H. Besley et al., “A clinically relevant functional model of type-2 cardio-renal syndrome with paraventricular changes consequent to chronic ischaemic heart failure,” Scientific Reports, vol. 10, no. 1, p. 1261, 2020.
[5] U. Kumar, N. Wettersten, and P. S. Garimella, “Cardiorenal syndrome: pathophysiology,” Cardiology Clinics, vol. 37, no. 3, pp. 251–265, 2019.
[6] X. Sheng, L. Lin, F. Guo et al., “Copeptin level in the early prediction of cardiorenal syndrome in rats,” Experimental and Therapeutic Medicine, vol. 16, no. 2, pp. 937–944, 2018.
[7] J. Rangaswami, V. Bhalla, J. E. A. Blair et al., “Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association,” Circulation, vol. 139, no. 16, pp. e840–e878, 2019.
[8] K. Damman and J. M. Testani, “The kidney in heart failure: an update,” European Heart Journal, vol. 36, no. 23, pp. 1437–1444, 2015.
[9] N. Singhania, S. Bansal, S. Mohandas, D. P. Nimmatoori, A. A. Ejaz, and G. Singhania, “Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease,” Context, vol. 9, pp. 1–9, 2020.
[10] A. A. Albashir, “Renin-angiotensin-aldosterone system (RAAS) inhibitors and coronavirus disease 2019 (COVID-
E. Bargagli, R. M. Refini, M. d'Alessandro et al., "Metabolic dysregulation in idiopathic pulmonary fibrosis," *International Journal of Molecular Sciences*, vol. 21, no. 16, p. 5663, 2020.

D. Sztechman, K. Czarzasta, A. Cudnoch-Jedrzejewska, E. Szczepanska-Sadowska, and T. Zera, "Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries," *Journal of Physiology and Pharmacology*, vol. 69, no. 6, 2018.

D. P. Leong, M. M. JJ, P. G. Joseph, and S. Yusuf, "From ACE inhibitors/ARBs to ARNi in coronary artery disease and heart failure (part 2/5)," *Journal of the American College of Cardiology*, vol. 74, no. 5, pp. 683–698, 2019.

J. Wang, C. Gareri, and H. A. Rockman, "G-protein-coupled receptors in heart disease," *Circulation Research*, vol. 123, no. 6, pp. 716–735, 2018.

S. N. Patel, N. Fatima, R. Ali, and T. Hussain, "Emerging role of angiotensin AT2 receptor in anti-inflammation: an update," *Current Pharmaceutical Design*, vol. 26, no. 4, pp. 492–500, 2020.

M. R. Deshotels, H. Xia, S. Sirramula, E. Lazartigues, and C. M. Filipeau, "Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type 1 receptor-dependent mechanism," *Hypertension*, vol. 64, no. 6, pp. 1368–1375, 2014.

A. Offringa, R. Montijn, S. Singh, M. Paul, Y. M. Pinto, and S. J. Pinto-Sietsma, "The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system," *European Heart Journal-Cardiovascular Pharmacotherapy*, vol. 6, no. 5, pp. 317–325, 2020.

K. E. Ferraino, N. Cora, C. M. Pollard, A. Sizova, J. Maning, and A. Lymeropoulos, "Adrenal angiotensin II type 1 receptor biased signaling: the case for ‘biased’ inverse agonism for effective aldosterone suppression," *Cellular Signalling*, vol. 82, article 109967, 2021.

A. Vecchiola, C. A. Fuentes, I. Solar et al., "Eplerenone implantation improved adipose dysfunction averting RAAS activation and cell division," *Frontiers in endocrinology*, vol. 11, p. 223, 2020.

J. W. Funder, "Aldosterone and mineralocorticoid receptors-physiology and pathophysiology," *International Journal of Molecular Sciences*, vol. 18, no. 5, p. 1032, 2017.

E. Gomez-Sanchez and C. E. Gomez-Sanchez, "The multifaceted mineralocorticoid receptor," *Comprehensive Physiology*, vol. 4, no. 3, pp. 965–994, 2014.

B. M. Parker, S. L. Wertz, C. M. Pollard et al., "Novel insights into the crosstalk between mineralocorticoid receptor and G protein-coupled receptors in heart adverse remodeling and disease," *International Journal of Molecular Sciences*, vol. 19, no. 12, p. 3764, 2018.

J. Robaczewska, K. Kedziora-Kornatowska, M. Kozakiewicz et al., "Role of glutathione metabolism and glutathione-related antioxidant defense systems in hypertension," *Journal of Physiology and Pharmacology*, vol. 67, no. 3, pp. 331–337, 2016.

M. Guitart-Mampel, P. Urquiza, J. I. Borges, A. Lymeropoulos, and M. E. Solesio, "Impact of aldosterone on the failing myocardium: insights from mitochondria and adrenergic receptors signaling and function," *Cell*, vol. 10, no. 6, p. 1552, 2021.

A. A. Gonzalez, M. Gallardo, C. Cespedes, and C. P. Vio, "Potassium intake prevents the induction of the renin-angiotensin system and increases medullary ACE2 and COX-2 in the kidneys of angiotensin II-dependent hypertensive rats," *Frontiers in Pharmacology*, vol. 10, p. 1212, 2019.

L. Xiao, B. Xu, L. Zhou et al., "Wnt/β-catenin regulates blood pressure and kidney injury in rats," *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1865, no. 6, pp. 1313–1322, 2019.

L. Ren, X. Lu, and A. H. J. Danser, "Revisiting the brain renin-angiotensin system-focus on novel therapies," *Current Hypertension Reports*, vol. 21, no. 4, p. 28, 2019.

A. Nehme, F. A. Zouein, Z. D. Zayeri, and K. Zibara, "An update on the tissue renin angiotensin system and its role in physiology and pathology," *Journal of cardiovascular development and disease*, vol. 6, no. 2, p. 14, 2019.

A. Clementi, G. M. Virzi, G. G. Battaglia, and C. Ronco, "Neurohormonal, endocrine, and immune dysregulation and inflammation in cardiorenal syndrome," *Cardiorenal medicine*, vol. 9, no. 5, pp. 265–273, 2019.

K. Rafiq, T. Noma, Y. Fujisawa et al., "Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation," *Circulation*, vol. 125, no. 11, pp. 1402–1413, 2012.

R. Ramchandra, D. T. Xing, M. Matear, G. Lambert, A. M. Allen, and C. N. May, "Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure," *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, vol. 317, no. 3, pp. R386–R396, 2019.

C. P. C. Ow, J. P. Ngo, M. M. Ullah, L. M. Hilliard, and R. G. Evans, "Renal hypoxia in kidney disease: cause or consequence?", *Acta Physiologica*, vol. 222, no. 4, article e12999, 2018.

D. M. Patel, M. Rose, and M. E. Cooper, "Glucose and blood pressure-dependent pathways-the progression of diabetic kidney disease," *International Journal of Molecular Sciences*, vol. 21, no. 6, p. 2218, 2020.

G. Jia, J. Habibi, A. R. Aroor et al., "Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females," *Circulation Research*, vol. 118, no. 6, pp. 935–943, 2016.

I. Mazak, A. Fiebeler, D. N. Muller et al., "Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells," *Circulation*, vol. 109, no. 22, pp. 2792–2800, 2004.

M. Reina-Couto, J. Afonso, J. Carvalho et al., "Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment," *Biomedicine & Pharmacotherapy*, vol. 133, article 110938, 2021.

S. Abolhasani, S. V. Shahbazloo, H. M. Saadati, N. Mahmodi, and N. Khanbaeia, "Evaluation of serum levels of inflammation, fibrinolysis and oxidative stress markers in coronary artery disease prediction: a cross-sectional study," *Arquivos Brasileiros de Cardiologia*, vol. 113, no. 4, pp. 667–674, 2019.

Z. Zhu, J. Li, and X. Zhang, "Astragaloside IV protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation," *Medical Science Monitor*, vol. 25, pp. 2132–2140, 2019.

M. Y. Wu, C. J. Li, M. F. Hou, and P. Y. Chu, "New insights into the role of inflammation in the pathogenesis of..."
atherosclerosis,” International Journal of Molecular Sciences, vol. 18, no. 10, p. 2034, 2017.

[40] P. T. Kovanen, “Mast cells as potential accelerators of human atherosclerosis—from early to late lesions,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4479, 2019.

[41] A. V. Poznyak, W. K. Wu, A. A. Melnichenko et al., “Signaling pathways and key genes involved in regression of foam cell formation in atherosclerosis,” Cell, vol. 9, no. 3, p. 584, 2020.

[42] P. Libby, “Inflammation in atherosclerosis—no longer a theory,” Clinical Chemistry, vol. 67, no. 1, pp. 131–142, 2021.

[43] N. Akhter, A. Madhoun, H. Arefanian et al., “Oxidative stress induces expression of the toll-like receptors (TLRs) 2 and 4 in the human peripheral blood mononuclear cells: implications for metabolic inflammation,” Cellular Physiology and Biochemistry, vol. 53, no. 1, pp. 1–18, 2019.

[44] F. A. Sumi, B. Sikder, M. M. Rahman et al., “Phenolic content analysis of aloe vera gel and evaluation of the effect of aloe gel supplementation on oxidative stress and fibrosis in isoprenaline-administered cardiac damage in rats,” Preventive nutrition and food science, vol. 24, no. 3, pp. 254–264, 2019.

[45] Y. Pu, D. Wu, X. Lu, and L. Yang, “Effects of GCN2/eIF2α on myocardial ischemia/hypoxia reperfusion and myocardial cells injury,” American Journal of Translational Research, vol. 11, no. 9, pp. 5586–5598, 2019.

[46] D. Chen, Z. Li, P. Bao et al., “Nrf2 deficiency aggravates angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflammation,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1865, no. 6, pp. 1253–1264, 2019.

[47] J. P. Ferreira, P. Rossignol, and F. Zannad, “Renin-angiotensin-aldosterone system and kidney interactions in heart failure,” Journal of the Renin-Angiotensin- Aldosterone System, vol. 20, no. 4, p. 147032031989415, 2019.

[48] R. Wang, Y. Luo, Y. Lu et al., “Maggot extracts alleviate inflammation and oxidative stress in acute experimental colitis via the activation of Nrf2,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 4703253, 18 pages, 2019.

[49] A. Atici, S. Emet, R. Cakmak et al., “Type I cardiorenal syndrome in patients with acutely decompensated heart failure: the importance of new renal biomarkers,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 11, pp. 3534–3543, 2018.

[50] Y. L. Liao, C. C. Chou, and Y. J. Lee, “The association of indoxyl sulfate with fibroblast growth factor-23 in cats with chronic kidney disease,” Journal of Veterinary Internal Medicine, vol. 33, no. 2, pp. 686–693, 2019.

[51] S. Lekawaniwijit, “Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome,” Toxins, vol. 10, no. 9, p. 352, 2018.

[52] J. S. Mathew, M. C. Sachs, R. Katz et al., “Fibroblast growth factor-23 and incident atrial fibrillation,” Circulation, vol. 130, no. 4, pp. 298–307, 2014.

[53] J. A. Navarro-Garcia, C. Delgado, M. Fernandez-Velasco et al., “Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes,” Nephrology, Dialysis, Transplantation, vol. 34, no. 11, pp. 1864–1875, 2019.

[54] H. Hao, X. Li, Q. Li et al., “FGF23 promotes myocardial fibrosis in mice through activation of β-catenin,” Oncotarget, vol. 7, no. 40, pp. 64649–64664, 2016.

[55] I. Böckmann, J. Lischka, B. Richter et al., “FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4634, 2019.

[56] M. Leihit-Neisler, R. Große Siemer, K. Flasbart et al., “Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease,” Nephrology, Dialysis, Transplantation, vol. 31, no. 7, pp. 1088–1099, 2016.

[57] E. R. Smith, S. J. Tan, S. G. Holt, and T. D. Hewitson, “FGF23 is synthesized locally by renal tubules and activates injury—primed fibroblasts,” Scientific Reports, vol. 7, no. 1, p. 3345, 2017.

[58] S. Eloit, D. Schneditz, T. Cornelis et al., “Protein-bound uremic toxin profiling as a tool to optimize hemodialysis,” PLoS One, vol. 11, no. 1, article e0147159, 2016.

[59] J. Pei, R. Juni, M. Harakalova et al., “Indoxyl sulfate stimulates angiogenesis by regulating reactive oxygen species production via CYP1B1,” Toxins, vol. 11, no. 8, p. 454, 2019.

[60] H. Han, J. Zhu, Z. Zhu et al., “p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes,” Journal of the American Heart Association, vol. 4, no. 6, article e001852, 2015.

[61] S. Zelzer, D. Enko, S. Pilz, A. Tomaschitz, W. März, and A. Meinitzer, “Myeloperoxidase, asymmetric dimethylarginine and the renin-angiotensin- aldosterone-system in cardiovascular risk patients: cross-sectional findings from the Ludwigsafen Risk and Cardiovascular Health (LURIC) study,” Clinical Biochemistry, vol. 50, no. 13-14, pp. 739–745, 2017.

[62] Y. Arlouskaya, A. Sawicka, M. Głowala et al., “Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) concentrations in patients with obesity and the risk of obstructive sleep apnea (OSA),” Journal of Clinical Medicine, vol. 8, no. 6, p. 897, 2019.

[63] K. Cordts, D. Seelig, N. Lund et al., “Association of asymmetric dimethylarginine and diastolic dysfunction in patients with hypertrophic cardiomyopathy,” Biomolecules, vol. 9, no. 7, p. 277, 2019.

[64] A. V. Poznyak, N. G. Nikiforov, A. M. Markin et al., “Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis,” Frontiers in Pharmacology, vol. 11, article 613780, 2021.

[65] J. Zhang, T. Bottiglieri, and P. A. Mccullough, “The central role of endothelial dysfunction in cardiorenal syndrome,” Cardio Renal Med, vol. 7, no. 2, pp. 104–117, 2017.

[66] T. Oda, M. Terauchi, K. Kato, A. Hirose, and N. Miyasaka, “Effects of grape seed proanthocyanidin extract on vascular endothelial function in participants with prehypertension: a randomized, double-blind, placebo-controlled study,” Nutrients, vol. 11, no. 12, p. 2844, 2019.

[67] J. Zhang, M. K. Fallahzadeh, and P. A. Mccullough, “Aging male spontaneously hypertensive rat as an animal model for the evaluation of the interplay between contrast—induced acute kidney injury and cardiorenal syndrome in humans,” Cardio Renal Med, vol. 7, no. 1, pp. 1–10, 2016.

[68] I. Amador-Martinez, R. Perez-Villalva, N. Uribe, C. Cortés-González, N. A. Bobadilla, and J. Barrera-Chimal, “Reduced endothelial nitric oxide synthase activation contributes to cardiovascular injury during chronic kidney disease progression,” American Journal of Physiology. Renal Physiology, vol. 317, no. 2, pp. F275–F285, 2019.

[69] I. E. Beldhuis, K. W. Streng, J. M. Ter Maaten et al., “Renin-angiotensin system inhibition, worsening renal function, and
outcome in heart failure patients with reduced and preserved ejection fraction,” *Circulation. Heart Failure*, vol. 10, no. 2, 2017.

[70] E. Vizzardi, S. Nodari, G. Caretta et al., “Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms,” *The American Journal of the Medical Sciences*, vol. 347, no. 4, pp. 271–276, 2014.

[71] Y. Yan, C. Wang, Y. Lu et al., “Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma,” *Journal of Physiology and Biochemistry*, vol. 74, no. 1, pp. 17–24, 2018.

[72] R. B. Patel, G. C. Fonarow, S. J. Greene et al., “Kidney function and outcomes in patients hospitalized with heart failure,” *Journal of the American College of Cardiology*, vol. 78, no. 4, pp. 330–343, 2021.

[73] F. R. Mc Causland, M. P. Lefkowitz, B. Claggett et al., “Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction,” *Circulation*, vol. 142, no. 13, pp. 1236–1245, 2020.

[74] K. Damman, M. Gori, B. Claggett et al., “Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure,” *JACC Heart Fail*, vol. 6, no. 6, pp. 489–498, 2018.

[75] P. S. Jhund, S. D. Solomon, K. F. Docherty et al., “Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction,” *Circulation*, vol. 143, no. 4, pp. 298–309, 2021.

[76] F. Zannad, J. P. Ferreira, S. J. Pocock et al., “Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function,” *Circulation*, vol. 143, no. 4, pp. 310–321, 2021.

[77] V. Perkovic, M. J. Jardine, B. Neal et al., “Canagliflozin and renal outcomes in type 2 diabetes and nephropathy,” *The New England Journal of Medicine*, vol. 380, no. 24, pp. 2295–2306, 2019.

[78] H. Yasuda and S. Isobe, “Dapagliflozin in patients with chronic kidney disease,” *The New England Journal of Medicine*, vol. 384, no. 4, p. 389, 2021.

[79] J. L. Pouchelon, C. E. Atkins, C. Bussadori et al., “Cardiovascular–renal axis disorders in the domestic dog and cat: a veterinary consensus statement,” *The Journal of Small Animal Practice*, vol. 56, no. 9, pp. 537–552, 2015.

[80] A. Ogawa-Akiyama, H. Sugiyama, M. Kitagawa et al., “Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease,” *PloS One*, vol. 13, no. 3, article e0193695, 2018.

[81] B. Szczepankiewicz, U. Paslawska, N. Siwińska, K. Plens, and R. Pasławski, “Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs,” *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 22, no. 1, p. 147032032199508, 2021.

[82] B. S. CHOI, H. S. MOON, S. H. SEO, and C. HYUN, “Evaluation of serum cystatin-C and symmetric dimethylarginine concentrations in dogs with heart failure from chronic mitral valvular insufficiency,” *The Journal of Veterinary Medical Science*, vol. 79, no. 1, pp. 41–46, 2017.

[83] M. Pohl, H. Kaminski, H. Castrop et al., ”Intrarenal renin angiotensin system revisited,” *The Journal of Biological Chemistry*, vol. 285, no. 53, pp. 41935–41946, 2010.

[84] A. Nishiyama and H. Kobori, “Independent regulation of renin-angiotensin-aldosterone system in the kidney,” *Clinical and Experimental Nephrology*, vol. 22, no. 6, pp. 1231–1239, 2018.

[85] M. Carlstrom and M. F. Montenegro, “Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease,” *Journal of Internal Medicine*, vol. 285, no. 1, pp. 2–18, 2019.

[86] N. de Las Heras, V. M. Martín Giménez, L. Ferder, W. Manucha, and V. Lahera, “Implications of oxidative stress and potential role of mitochondrial dysfunction in COVID-19: therapeutic effects of vitamin D,” *Antioxidants*, vol. 9, no. 9, p. 897, 2020.

[87] M. Sepidarkish, F. Farsi, M. Akbari-Fakhribadi et al., “The effect of vitamin D supplementation on oxidative stress parameters: a systematic review and meta-analysis of clinical trials,” *Pharmacological Research*, vol. 139, pp. 141–152, 2019.